Floatz logo

THIOGUANINE ANHYDROUS

Neutropenia

SWOG Cancer Research NetworkSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Neutropenia cohort.

Asset / SponsorPhaseRating
f-627
EVIVE Biotechnology
Phase 3BBB
PEGFILGRASTIM
Affiliated Hospital of North Sichuan Medical College
Phase 4BBB
FILGRASTIM
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4BBB
Cefepime
Hospital Universitari Vall d'Hebron Research Institute
Phase 4BB
Spi-2012
Spectrum Pharmaceuticals, Inc
Phase 3BB

View all 50 →

Same molecule, other indications

THIOGUANINE ANHYDROUS is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
lymphoblastic lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →